Logo image of ARTV

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ARTV - US04317A1079 - Common Stock

3.12 USD
+0.04 (+1.3%)
Last: 12/9/2025, 4:10:04 PM
Fundamental Rating

3

ARTV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. ARTV has a great financial health rating, but its profitability evaluates not so good. ARTV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARTV had negative earnings in the past year.
ARTV had a negative operating cash flow in the past year.
ARTV Yearly Net Income VS EBIT VS OCF VS FCFARTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.20%, ARTV is in line with its industry, outperforming 46.89% of the companies in the same industry.
The Return On Equity of ARTV (-61.28%) is better than 60.45% of its industry peers.
Industry RankSector Rank
ROA -53.2%
ROE -61.28%
ROIC N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARTV Yearly ROA, ROE, ROICARTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTV Yearly Profit, Operating, Gross MarginsARTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARTV has more shares outstanding than it did 1 year ago.
ARTV has a worse debt/assets ratio than last year.
ARTV Yearly Shares OutstandingARTV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
ARTV Yearly Total Debt VS Total AssetsARTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ARTV has an Altman-Z score of -1.56. This is a bad value and indicates that ARTV is not financially healthy and even has some risk of bankruptcy.
ARTV has a Altman-Z score (-1.56) which is in line with its industry peers.
There is no outstanding debt for ARTV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC8.77%
ARTV Yearly LT Debt VS Equity VS FCFARTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ARTV has a Current Ratio of 11.65. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
ARTV has a better Current ratio (11.65) than 85.88% of its industry peers.
ARTV has a Quick Ratio of 11.65. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.65, ARTV belongs to the best of the industry, outperforming 85.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.65
Quick Ratio 11.65
ARTV Yearly Current Assets VS Current LiabilitesARTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

ARTV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.09%.
Looking at the last year, ARTV shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
ARTV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.95% yearly.
EPS 1Y (TTM)7.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.86%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ARTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
ARTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 189.66% yearly.
EPS Next Y35.88%
EPS Next 2Y17.05%
EPS Next 3Y17.4%
EPS Next 5Y8.25%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARTV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTV Price Earnings VS Forward Price EarningsARTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTV Per share dataARTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as ARTV's earnings are expected to grow with 17.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.05%
EPS Next 3Y17.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARTV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (12/9/2025, 4:10:04 PM)

3.12

+0.04 (+1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-23 2026-03-23
Inst Owners71.23%
Inst Owner Change-1.5%
Ins Owners0.82%
Ins Owner Change-1.53%
Market Cap76.56M
Revenue(TTM)N/A
Net Income(TTM)-79.19M
Analysts85
Price Target17.34 (455.77%)
Short Float %1.19%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-5.74%
Max EPS beat(2)0.83%
EPS beat(4)2
Avg EPS beat(4)-1.28%
Min EPS beat(4)-14.53%
Max EPS beat(4)14.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.66%
PT rev (3m)10.39%
EPS NQ rev (1m)10.26%
EPS NQ rev (3m)10.26%
EPS NY rev (1m)2.67%
EPS NY rev (3m)1.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-3.23
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0
BVpS5.27
TBVpS5.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.2%
ROE -61.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.65
Quick Ratio 11.65
Altman-Z -1.56
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)238.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)131.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.86%
EPS Next Y35.88%
EPS Next 2Y17.05%
EPS Next 3Y17.4%
EPS Next 5Y8.25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.66%
EBIT growth 1Y-8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.03%
OCF growth 3YN/A
OCF growth 5YN/A

ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ

What is the ChartMill fundamental rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARTV.


What is the valuation status of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARTIVA BIOTHERAPEUTICS INC (ARTV). This can be considered as Overvalued.


How profitable is ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

The Earnings per Share (EPS) of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to grow by 35.88% in the next year.